US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OnKure Therapeutics, Inc.

2.60

-0.0400-1.52%

Post-market: 2.600.00000.00%16:10 EST

Volume:69.36K

Turnover:180.62K

Market Cap:35.23M

PE:-0.55

High:2.74

Open:2.64

Low:2.50

Close:2.64

52wk High:5.60

52wk Low:1.70

Shares:13.55M

Float Shares:5.81M

Volume Ratio:0.64

T/O Rate:1.19%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.7614

EPS(LYR):-15.2805

ROE:-207.36%

ROA:-96.53%

PB:0.53

PE(LYR):-0.17

Loading ...

Overview Company News Filings

Evercore ISI Keeps Their Buy Rating on OnKure Therapeutics (OKUR)

Onkure Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing

BRIEF-Onkure Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing

OnKure Therapeutics files $200M mixed securities shelf

Onkure Therapeutics Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing

THOMSON REUTERS

OnKure Therapeutics Reports Q3 2025 Results and Advances OKI-219 Clinical Trials

Onkure Therapeutics Inc expected to post a loss of $1.20 a share - Earnings Preview

OnKure Therapeutics CFO Jason A. Leverone Reports Disposal of Common Shares

OnKure Therapeutics Price Target Maintained With a $34.00/Share by HC Wainwright & Co.

Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

OnKure Therapeutics Q2 2025 Results: Net Loss Widened to $15.4M, EPS at $1.14, R&D Expenses Increased to $12.6M

Onkure Therapeutics Inc - Cash Position of $83.4 Mln Expected to Provide Cash Runway Into Q4 2026

THOMSON REUTERS

Onkure Therapeutics Inc - Net Loss $1.14 per Share in Q2 2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OKUR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OKUR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OKUR\",,,,,undefined,":{"symbol":"OKUR","market":"US","secType":"STK","nameCN":"OnKure Therapeutics, Inc.","latestPrice":2.6,"timestamp":1771621200000,"preClose":2.64,"halted":0,"volume":69362,"hourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.6,"latestTime":"16:10 EST","volume":4,"amount":10.4,"timestamp":1771621804579,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.015151515151515164,"floatShares":5808240,"shares":13548199,"eps":-4.76145,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"02-20 16:00:00 EST","open":2.64,"high":2.74,"low":2.4962,"amount":180617.4738,"amplitude":0.092348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.76145,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":0,"adr":0,"listingDate":1617940800000,"exchange":"NASDAQ","adjPreClose":2.64,"preHourTrading":{"tag":"盘前","latestPrice":2.73,"preClose":2.64,"latestTime":"08:00 EST","volume":3,"amount":8.19,"timestamp":1771592401127,"change":0.09,"changeRate":0.034091,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.6,"latestTime":"16:10 EST","volume":4,"amount":10.4,"timestamp":1771621804579,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6394154708719988},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OKUR\",,,,,undefined,":{"symbol":"OKUR","floatShares":5808240,"roa":"-96.53%","roe":"-207.36%","lyrEps":-15.280509,"volumeRatio":0.6394154708719988,"shares":13548199,"dividePrice":0,"high":2.74,"amplitude":0.092348,"preClose":2.64,"low":2.4962,"week52Low":1.7,"pbRate":"0.53","week52High":5.6,"institutionHeld":0,"latestPrice":2.6,"eps":-4.76145,"divideRate":0,"volume":69362,"delay":0,"ttmEps":-4.76145,"open":2.64,"prevYearClose":2.9,"prevWeekClose":2.42,"prevMonthClose":2.64,"prevQuarterClose":2.9,"fiveDayClose":2.41,"twentyDayClose":3.05,"sixtyDayClose":2.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OKUR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"OKUR","fiscalQuarterEnding":"2025/06","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":-1.14},{"market":"US","date":"2025-05-06","symbol":"OKUR","fiscalQuarterEnding":"2025/03","expectedEps":-1.32,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746504000000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2025-03-10","symbol":"OKUR","fiscalQuarterEnding":"2024/12","expectedEps":-0.86,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741579200000,"reportTimeType":"post","actualEps":-1.37}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OKUR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OKUR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1745989200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/OKUR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"OKUR","date":"2026-02-20","current":-0.546052,"percent":0.78635,"low":-5.826698,"twenty":-1.701522,"median":-0.649432,"eighty":-0.562001,"high":-0.416488,"avg":-1.297524,"sd":1.329739,"marketCap":35767245},"quantilePoints":[{"date":"2024-10-18","current":-0.566743,"twenty":-0.590487,"median":-0.58695,"eighty":-0.578615,"marketCap":23873500},{"date":"2024-10-25","current":-5.440362,"twenty":-1.566804,"median":-0.588529,"eighty":-0.583857,"marketCap":229169826},{"date":"2024-10-31","current":-5.53853,"twenty":-5.51383,"median":-0.595209,"eighty":-0.585182,"marketCap":233305021},{"date":"2024-11-08","current":-5.443529,"twenty":-5.51383,"median":-5.168028,"eighty":-0.586445,"marketCap":229303220},{"date":"2024-11-15","current":-5.044864,"twenty":-5.465063,"median":-5.164656,"eighty":-0.588845,"marketCap":225434812},{"date":"2024-11-22","current":-4.773218,"twenty":-5.441629,"median":-5.044864,"eighty":-0.591244,"marketCap":213296014},{"date":"2024-11-29","current":-4.603066,"twenty":-5.421362,"median":-4.955311,"eighty":-0.594567,"marketCap":205692591},{"date":"2024-12-06","current":-4.23888,"twenty":-5.387795,"median":-4.77471,"eighty":-2.052213,"marketCap":189418599},{"date":"2024-12-13","current":-3.232892,"twenty":-5.327258,"median":-4.623962,"eighty":-3.414388,"marketCap":144465030},{"date":"2024-12-20","current":-2.403027,"twenty":-5.244271,"median":-4.603066,"eighty":-2.584523,"marketCap":107381670},{"date":"2024-12-27","current":-2.444819,"twenty":-5.224724,"median":-4.480676,"eighty":-2.411385,"marketCap":109249178},{"date":"2025-01-03","current":-2.543328,"twenty":-5.168028,"median":-4.415003,"eighty":-2.435864,"marketCap":113651159},{"date":"2025-01-10","current":-2.331384,"twenty":-5.162633,"median":-4.235895,"eighty":-2.394669,"marketCap":104180229},{"date":"2025-01-17","current":-1.794061,"twenty":-5.159079,"median":-4.098579,"eighty":-2.308697,"marketCap":80169421},{"date":"2025-01-24","current":-1.605998,"twenty":-5.09033,"median":-3.232892,"eighty":-1.908093,"marketCap":71765638},{"date":"2025-01-31","current":-1.740329,"twenty":-5.041282,"median":-2.694077,"eighty":-1.735553,"marketCap":77768340},{"date":"2025-02-07","current":-1.698537,"twenty":-4.988744,"median":-2.570194,"eighty":-1.722418,"marketCap":75900833},{"date":"2025-02-14","current":-1.680626,"twenty":-4.917698,"median":-2.540343,"eighty":-1.700328,"marketCap":75100472},{"date":"2025-02-21","current":-1.629879,"twenty":-4.846055,"median":-2.485118,"eighty":-1.698537,"marketCap":72832785},{"date":"2025-02-28","current":-1.459727,"twenty":-4.775009,"median":-2.435864,"eighty":-1.629879,"marketCap":65229362},{"date":"2025-03-07","current":-1.510474,"twenty":-4.72068,"median":-2.35825,"eighty":-1.588087,"marketCap":67497050},{"date":"2025-03-14","current":-1.170006,"twenty":-4.634708,"median":-2.331384,"eighty":-1.520623,"marketCap":61627741},{"date":"2025-03-21","current":-1.2754,"twenty":-4.622768,"median":-2.038842,"eighty":-1.494951,"marketCap":67179130},{"date":"2025-03-28","current":-1.196325,"twenty":-4.613812,"median":-1.835853,"eighty":-1.463309,"marketCap":63014023},{"date":"2025-04-04","current":-0.992261,"twenty":-4.603066,"median":-1.777643,"eighty":-1.2754,"marketCap":52265363},{"date":"2025-04-11","current":-0.755037,"twenty":-4.555304,"median":-1.746299,"eighty":-1.238668,"marketCap":39770044},{"date":"2025-04-17","current":-0.747384,"twenty":-4.482467,"median":-1.737344,"eighty":-1.209875,"marketCap":39366970},{"date":"2025-04-25","current":-0.675962,"twenty":-4.474705,"median":-1.713463,"eighty":-1.144127,"marketCap":35604938},{"date":"2025-05-02","current":-0.6377,"twenty":-4.44366,"median":-1.701522,"eighty":-1.004505,"marketCap":33589565},{"date":"2025-05-09","current":-0.454974,"twenty":-4.341569,"median":-1.694059,"eighty":-0.784115,"marketCap":26871652},{"date":"2025-05-16","current":-0.468834,"twenty":-4.237686,"median":-1.629879,"eighty":-0.752996,"marketCap":27690262},{"date":"2025-05-23","current":-0.489317,"twenty":-4.231716,"median":-1.626894,"eighty":-0.697899,"marketCap":28900031},{"date":"2025-05-30","current":-0.583311,"twenty":-4.22694,"median":-1.591073,"eighty":-0.663208,"marketCap":34451517},{"date":"2025-06-06","current":-0.654223,"twenty":-4.098579,"median":-1.549281,"eighty":-0.645352,"marketCap":38639741},{"date":"2025-06-13","current":-0.651936,"twenty":-3.686632,"median":-1.511967,"eighty":-0.647361,"marketCap":38504637},{"date":"2025-06-20","current":-0.553574,"twenty":-3.32364,"median":-1.503011,"eighty":-0.6377,"marketCap":32695165},{"date":"2025-06-27","current":-0.576449,"twenty":-3.001246,"median":-1.480623,"eighty":-0.606186,"marketCap":34046205},{"date":"2025-07-03","current":-0.544424,"twenty":-2.803631,"median":-1.468682,"eighty":-0.59365,"marketCap":32154749},{"date":"2025-07-11","current":-0.583311,"twenty":-2.690793,"median":-1.364985,"eighty":-0.585652,"marketCap":34451517},{"date":"2025-07-18","current":-0.544424,"twenty":-2.634673,"median":-1.2754,"eighty":-0.583311,"marketCap":32154749},{"date":"2025-07-25","current":-0.542136,"twenty":-2.584523,"median":-1.253011,"eighty":-0.577821,"marketCap":32019645},{"date":"2025-08-01","current":-0.505536,"twenty":-2.568403,"median":-1.219282,"eighty":-0.570959,"marketCap":29857981},{"date":"2025-08-08","current":-0.459786,"twenty":-2.55288,"median":-1.202702,"eighty":-0.560894,"marketCap":27155901},{"date":"2025-08-15","current":-0.598959,"twenty":-2.539746,"median":-1.170006,"eighty":-0.552659,"marketCap":36124995},{"date":"2025-08-22","current":-0.607932,"twenty":-2.515865,"median":-1.091743,"eighty":-0.553574,"marketCap":36666194},{"date":"2025-08-29","current":-0.630365,"twenty":-2.481834,"median":-0.992261,"eighty":-0.556319,"marketCap":38019190},{"date":"2025-09-05","current":-0.603445,"twenty":-2.459148,"median":-0.7984,"eighty":-0.559979,"marketCap":36395595},{"date":"2025-09-12","current":-0.547363,"twenty":-2.441237,"median":-0.779269,"eighty":-0.559219,"marketCap":33013104},{"date":"2025-09-19","current":-0.556336,"twenty":-2.422729,"median":-0.755037,"eighty":-0.552201,"marketCap":33554303},{"date":"2025-09-26","current":-0.569796,"twenty":-2.38631,"median":-0.742282,"eighty":-0.553574,"marketCap":34366100},{"date":"2025-10-03","current":-0.628121,"twenty":-2.358847,"median":-0.696368,"eighty":-0.554679,"marketCap":37883890},{"date":"2025-10-10","current":-0.70215,"twenty":-2.355265,"median":-0.682961,"eighty":-0.557061,"marketCap":42348777},{"date":"2025-10-17","current":-0.646068,"twenty":-2.345713,"median":-0.675962,"eighty":-0.559219,"marketCap":38966287},{"date":"2025-10-24","current":-0.668501,"twenty":-2.28601,"median":-0.669623,"eighty":-0.561583,"marketCap":40319283},{"date":"2025-10-31","current":-0.751502,"twenty":-2.19765,"median":-0.675962,"eighty":-0.562861,"marketCap":45325369},{"date":"2025-11-07","current":-0.70888,"twenty":-2.064514,"median":-0.682961,"eighty":-0.564537,"marketCap":42754676},{"date":"2025-11-14","current":-0.670407,"twenty":-1.908093,"median":-0.675901,"eighty":-0.567067,"marketCap":42541344},{"date":"2025-11-21","current":-0.559384,"twenty":-1.877048,"median":-0.672987,"eighty":-0.567067,"marketCap":35496281},{"date":"2025-11-28","current":-0.642651,"twenty":-1.828092,"median":-0.670575,"eighty":-0.566905,"marketCap":40780078},{"date":"2025-12-05","current":-0.561519,"twenty":-1.796449,"median":-0.668272,"eighty":-0.562792,"marketCap":35631763},{"date":"2025-12-12","current":-0.689622,"twenty":-1.787494,"median":-0.669454,"eighty":-0.563801,"marketCap":43760682},{"date":"2025-12-19","current":-0.664002,"twenty":-1.760628,"median":-0.668272,"eighty":-0.566905,"marketCap":42134898},{"date":"2025-12-26","current":-0.60849,"twenty":-1.75824,"median":-0.664002,"eighty":-0.567553,"marketCap":38612367},{"date":"2026-01-02","current":-0.619166,"twenty":-1.748687,"median":-0.663208,"eighty":-0.567553,"marketCap":39289777},{"date":"2026-01-09","current":-0.610625,"twenty":-1.741523,"median":-0.658197,"eighty":-0.568573,"marketCap":38747849},{"date":"2026-01-16","current":-0.642651,"twenty":-1.737941,"median":-0.661086,"eighty":-0.569434,"marketCap":40780078},{"date":"2026-01-23","current":-0.651191,"twenty":-1.73197,"median":-0.657597,"eighty":-0.569712,"marketCap":41322006},{"date":"2026-01-30","current":-0.58287,"twenty":-1.719433,"median":-0.655987,"eighty":-0.571043,"marketCap":36986583},{"date":"2026-02-06","current":-0.495333,"twenty":-1.713463,"median":-0.654223,"eighty":-0.567553,"marketCap":31431821},{"date":"2026-02-13","current":-0.514548,"twenty":-1.706298,"median":-0.651563,"eighty":-0.563419,"marketCap":32651159},{"date":"2026-02-20","current":-0.563654,"twenty":-1.701522,"median":-0.649432,"eighty":-0.562001,"marketCap":35767245}],"updateTime":1771809891015},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OKUR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606831867","title":"Evercore ISI Keeps Their Buy Rating on OnKure Therapeutics (OKUR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606831867","media":"TIPRANKS","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606831867?lang=en_us&edition=fundamental","pubTime":"2026-01-27 18:46","pubTimestamp":1769510762,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Jonathan Miller maintained a Buy rating on OnKure Therapeutics yesterday. The company’s shares closed yesterday at $2.76. Mill...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-onkure-therapeutics-okur-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-onkure-therapeutics-okur-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKUR"],"gpt_icon":0},{"id":"2584929923","title":"Onkure Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929923","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929923?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:00","pubTimestamp":1763571611,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Onkure Therapeutics Inc ::*ONKURE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202523:06:22 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD1HsSJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","BK4539","BK4139"],"gpt_icon":0},{"id":"2581044848","title":"BRIEF-Onkure Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581044848","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581044848?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:06","pubTimestamp":1762470382,"startTime":"0","endTime":"0","summary":"BRIEF-Onkure Therapeutics Inc Files For Mixed Shelf Of Up To $200 Million - SEC FilingNov 7  - Onkure Therapeutics Inc OKUR.O:ONKURE THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILINGSource text: [ID:n0001193125-25-270073]Further company coverage: OKUR.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI2QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKUR","BK4539"],"gpt_icon":0},{"id":"2581496830","title":"OnKure Therapeutics files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2581496830","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581496830?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:10","pubTimestamp":1762467020,"startTime":"0","endTime":"0","summary":"17:09 EST OnKure Therapeutics (OKUR) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onkure-therapeutics-files-200m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onkure-therapeutics-files-200m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","OKUR","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2581046455","title":"Onkure Therapeutics Inc Files for Mixed Shelf of up to $200 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581046455","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581046455?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:09","pubTimestamp":1762466972,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI2QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","OKUR"],"gpt_icon":0},{"id":"2581760010","title":"OnKure Therapeutics Reports Q3 2025 Results and Advances OKI-219 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2581760010","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581760010?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:14","pubTimestamp":1762463684,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics Inc. reported its third quarter 2025 financial results and provided a business update. The company announced that the first patients have been dosed in the triplet expansion arms of the PIKture-01 trial, which is evaluating OKI-219 in combination with fulvestrant and ribociclib, as well as in combination with trastuzumab and tucatinib, in patients with metastatic breast cancer. Clinical data from the single agent and fulvestrant combination arms of the PIKture-01 trial are maturing, with initial results from these and the triplet expansion arms expected in the first quarter of 2026. Significant progress was reported in OnKure's next-generation PI3Ka pan-mutant inhibitor program, with multiple candidates identified and an announcement planned for the first quarter of 2026. The company also noted an expansion into vascular malformations, with additional information to be provided in 2026. OKI-219 is OnKure's lead product candidate, described as a highly selective PI3k","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9yjMjp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","OKUR"],"gpt_icon":0},{"id":"2580211702","title":"Onkure Therapeutics Inc  expected to post a loss of $1.20 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580211702","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580211702?lang=en_us&edition=fundamental","pubTime":"2025-11-04 06:40","pubTimestamp":1762209608,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics Inc  expected to post a loss of $1.20 a share - Earnings Preview Onkure Therapeutics Inc OKUR.OQ OKUR.O is expected to  show no change in quarterly revenue when it reports  results","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nL8N3WF2JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","OKUR"],"gpt_icon":0},{"id":"2570031796","title":"OnKure Therapeutics CFO Jason A. Leverone Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2570031796","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570031796?lang=en_us&edition=fundamental","pubTime":"2025-09-25 07:41","pubTimestamp":1758757318,"startTime":"0","endTime":"0","summary":"Jason A. Leverone, Chief Financial Officer of Onkure Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL7dTslr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR","BK4139","BK4539"],"gpt_icon":0},{"id":"2562737030","title":"OnKure Therapeutics Price Target Maintained With a $34.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2562737030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562737030?lang=en_us&edition=fundamental","pubTime":"2025-08-26 22:44","pubTimestamp":1756219440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKUR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 26, 2025 10:44 ET (14:44 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","OKUR"],"gpt_icon":0},{"id":"2559624807","title":"Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559624807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559624807?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:40","pubTimestamp":1755031207,"startTime":"0","endTime":"0","summary":"Onkure Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryOnkure Therapeutics Inc OKUR.OQ reported a quarterly adjusted loss of $1.14 per share for the quarter ended June","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U41VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR"],"gpt_icon":0},{"id":"2559621198","title":"OnKure Therapeutics Q2 2025 Results: Net Loss Widened to $15.4M, EPS at $1.14, R&D Expenses Increased to $12.6M","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621198","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621198?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:21","pubTimestamp":1755030074,"startTime":"0","endTime":"0","summary":"OnKure Therapeutics, Inc. , a clinical-stage biopharmaceutical company, reported its financial results for the second quarter ending June 30, 2025. The company reported a net loss of $15.4 million, compared to a net loss of $14.1 million in the same quarter of 2024. Research and development expenses rose to $12.6 million from $10.8 million in the previous year, driven by increased clinical trial, outsourced manufacturing, and research expenses. General and administrative expenses saw a slight increase to $3.7 million from $3.6 million, attributed to higher personnel-related costs and professional service fees, partially offset by a reduction in legal expenses. The company's cash and cash equivalents stood at $83.4 million as of June 30, 2025, expected to support operations into the fourth quarter of 2026. OnKure is advancing its lead asset, OKI-219, with the PIKture-01 phase 1 clinical trial on track for data release in the fourth quarter of 2025. The trial includes new expansion arms ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDLbV99SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKUR"],"gpt_icon":0},{"id":"2559621728","title":"Onkure Therapeutics Inc - Cash Position of $83.4 Mln Expected to Provide Cash Runway Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621728?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029104,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA5KS7KS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OKUR","BK4539"],"gpt_icon":0},{"id":"2559621726","title":"Onkure Therapeutics Inc - Net Loss $1.14 per Share in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2559621726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559621726?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:05","pubTimestamp":1755029104,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nTUA5KS7KS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OKUR","BK4139","BK4539"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}